The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated by Repotrectinib, Taletrectinib, and NVL-520 by 2034. Additionally, the market for ROS1 inhibitors is expected to grow significantly in the coming years. This is due to the increasing biomarker testing rates, the increasing number of patients who are being diagnosed with different types of cancers, the growing awareness of ROS1 mutations, and entry of next-generation emerging ROS1 TKIs with superior CNS penetration and broader coverage of ROS1 resistance mutations than first-generation TKIs.
LAS VEGAS , Nov. 5, 2024 /PRNewswire/ -- DelveInsight's ROS1 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging ROS1 inhibitors, market share of individual therapies, and current and forecasted ROS1 inhibitors market size from 2020 to 2034, segmented into the 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ), the United Kingdom , and Japan ]. Key Takeaways from the ROS1 Inhibitors Market Report As per DelveInsight's analysis, the ROS-1 inhibitor market size in the 7MM for ROS-1 Non-small cell lung cancer (NSCLC) was estimated to be nearly USD 290 million in 2023, in which the US accounted for the maximum share of the total market.
In the US, the highest revenue was captured by XALKORI (crizotinib), which is anticipated to decline owing to the entry of next-gener.